COSCIENS BIOPHARMA INC (CSCI.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:CSCI - CA22112H1010 - Common Stock
2.8 CAD
-0.08 (-2.78%)
We assign a fundamental rating of 3 out of 10 to CSCI. CSCI was compared to 23 industry peers in the Biotechnology industry. The financial health of CSCI is average, but there are quite some concerns on its profitability. CSCI is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year CSCI has reported negative net income.
- In the past year CSCI has reported a negative cash flow from operations.
- CSCI had negative earnings in each of the past 5 years.
- CSCI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- CSCI has a Return On Assets (-62.48%) which is in line with its industry peers.
- With a Return On Equity value of -293.43%, CSCI perfoms like the industry average, outperforming 56.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.48% | ||
| ROE | -293.43% | ||
| ROIC | N/A |
ROA(3y)-32.96%
ROA(5y)-24.63%
ROE(3y)-65.43%
ROE(5y)-50.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With a decent Gross Margin value of 45.14%, CSCI is doing good in the industry, outperforming 73.91% of the companies in the same industry.
- CSCI's Gross Margin has improved in the last couple of years.
- CSCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.14% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.48%
GM growth 5Y19.79%
2. Health
2.1 Basic Checks
- CSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, CSCI has more shares outstanding
- The number of shares outstanding for CSCI has been increased compared to 5 years ago.
- CSCI has a better debt/assets ratio than last year.
2.2 Solvency
- CSCI has an Altman-Z score of -1.64. This is a bad value and indicates that CSCI is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -1.64, CSCI is in the better half of the industry, outperforming 73.91% of the companies in the same industry.
- CSCI has a Debt/Equity ratio of 0.39. This is a healthy value indicating a solid balance between debt and equity.
- CSCI has a Debt to Equity ratio of 0.39. This is comparable to the rest of the industry: CSCI outperforms 52.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.39 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.64 |
ROIC/WACCN/A
WACC7.67%
2.3 Liquidity
- CSCI has a Current Ratio of 3.47. This indicates that CSCI is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of CSCI (3.47) is better than 73.91% of its industry peers.
- A Quick Ratio of 3.03 indicates that CSCI has no problem at all paying its short term obligations.
- CSCI has a better Quick ratio (3.03) than 69.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.47 | ||
| Quick Ratio | 3.03 |
3. Growth
3.1 Past
- CSCI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.32%, which is quite impressive.
- The Revenue has grown by 41.78% in the past year. This is a very strong growth!
- The Revenue has been growing by 80.53% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)39.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.1%
Revenue 1Y (TTM)41.78%
Revenue growth 3Y21.84%
Revenue growth 5Y80.53%
Sales Q2Q%-20.74%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for CSCI. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- CSCI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
COSCIENS BIOPHARMA INC / CSCI.CA FAQ
What is the fundamental rating for CSCI stock?
ChartMill assigns a fundamental rating of 3 / 10 to CSCI.CA.
What is the valuation status for CSCI stock?
ChartMill assigns a valuation rating of 0 / 10 to COSCIENS BIOPHARMA INC (CSCI.CA). This can be considered as Overvalued.
How profitable is COSCIENS BIOPHARMA INC (CSCI.CA) stock?
COSCIENS BIOPHARMA INC (CSCI.CA) has a profitability rating of 2 / 10.